Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01689363
Other study ID # API-H001-CLN-A2
Secondary ID
Status Completed
Phase Phase 2
First received September 13, 2012
Last updated January 18, 2017
Start date September 2012
Est. completion date December 2012

Study information

Verified date January 2017
Source Amphastar Pharmaceuticals, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is designed to evaluate the allergenicity of Amphadase® in healthy volunteers using an intradermal skin test.


Recruitment information / eligibility

Status Completed
Enrollment 253
Est. completion date December 2012
Est. primary completion date November 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

Healthy volunteers of either gender; Those without clinically significant cardiovascular gastrointestinal, hepatic, neurological, psychiatric, endocrine, or other major systemic disease that would unduly risk the subject's safety or interfere with the interpretation of results, assessed according to the judgment of the Principal Investigator. A non-inclusive list which would not be exclusionary and define healthy individual for the purposes of this study are:

- hypothyroidism,

- stable hypertension except those subjects on beta blockers including ocular preparations,

- seasonal/perennial allergic rhinitis if able to wash out of antihistamines,

- stable, mild intermittent asthma (subjects using beta agonists as a monotherapy on an as-needed basis, excluding daily usage),

- migraine if not taking excluded medications,

- mild anxiety/depression if not taking excluded medications, and

- mild arthritic conditions if not taking excluded medications.

- Willingness and ability to sign an informed consent document;

- 18 - 80 years of age;

- Intact skin at the forearm ;

- Female participants are currently practicing effective birth control methods or abstinence.

Exclusion Criteria:

- Known allergy, hypersensitivity or contraindications to hyaluronidase, thimerosal, edetate disodium (EDTA);

- Use of medications within a duration considered to interfere with skin testing.

- Known dermographism which may interfere with skin testing.

- Pregnant or lactating women.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Hyaluronidase
Subjects received intradermal injections of 0.02 mL Amphadase® (hyaluronidase 150 USP units/mL) at two random sites on their forearms.
Histamine
Subjects received one intradermal injection of 0.02 mL Histatrol® (histamine base 0.1 mg/mL) at one random sites on their forearms.
Saline
Subjects received one intradermal injection of 0.02 mL saline at one random site on their forearm.

Locations

Country Name City State
United States Amphastar Site 0022 Eugene Oregon
United States Amphastar Site 0023 Lake Oswego Oregon
United States Amphastar Site 0026 Portland Oregon
United States Amphastar Site 0038 Renton Washington
United States Amphastar Site 0034 Seattle Washington

Sponsors (1)

Lead Sponsor Collaborator
Amphastar Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

References & Publications (13)

Agrawal A, McLure HA, Dabbs TR. Allergic reaction to hyaluronidase after a peribulbar injection. Anaesthesia. 2003 May;58(5):493-4. — View Citation

Ahluwalia HS, Lukaris A, Lane CM. Delayed allergic reaction to hyaluronidase: a rare sequel to cataract surgery. Eye (Lond). 2003 Mar;17(2):263-6. Review. — View Citation

Allergy testing. American College of Physicians. Ann Intern Med. 1989 Feb 15;110(4):317-20. — View Citation

Barbaud A, Reichert-Penetrat S, Tréchot P, Jacquin-Petit MA, Ehlinger A, Noirez V, Faure GC, Schmutz JL, Béné MC. The use of skin testing in the investigation of cutaneous adverse drug reactions. Br J Dermatol. 1998 Jul;139(1):49-58. — View Citation

Barr J, Kirkpatrick N, Dick A, Leonard L, Hawksworth G, Noble DW. Effects of adrenaline and hyaluronidase on plasma concentrations of lignocaine and bupivacaine after peribulbar anaesthesia. Br J Anaesth. 1995 Dec;75(6):692-7. — View Citation

Brydon CW, Basler M, Kerr WJ. An evaluation of two concentrations of hyaluronidase for supplementation of peribulbar anaesthesia. Anaesthesia. 1995 Nov;50(11):998-1000. — View Citation

Fisher MM, Bowey CJ. Intradermal compared with prick testing in the diagnosis of anaesthetic allergy. Br J Anaesth. 1997 Jul;79(1):59-63. — View Citation

Howard A, Mercer P, Nataraj HC, Kang BC. Bevel-down superior to bevel-up in intradermal skin testing. Ann Allergy Asthma Immunol. 1997 Jun;78(6):594-6. — View Citation

Kempeneers A, Dralands L, Ceuppens J. Hyaluronidase induced orbital pseudotumor as complication of retrobulbar anesthesia. Bull Soc Belge Ophtalmol. 1992;243:159-66. — View Citation

Minning CA Jr. Hyaluronidase allergy simulating expulsive choroidal hemorrhage. Arch Ophthalmol. 1994 May;112(5):585-6. — View Citation

Poulsen LK. In vivo and in vitro techniques to determine the biological activity of food allergens. J Chromatogr B Biomed Sci Appl. 2001 May 25;756(1-2):41-55. Review. — View Citation

Ruzicka T, Gerstmeier M, Przybilla B, Ring J. Allergy to local anesthetics: comparison of patch test with prick and intradermal test results. J Am Acad Dermatol. 1987 Jun;16(6):1202-8. — View Citation

Szépfalusi Z, Nentwich I, Dobner M, Pillwein K, Urbanek R. IgE-mediated allergic reaction to hyaluronidase in paediatric oncological patients. Eur J Pediatr. 1997 Mar;156(3):199-203. — View Citation

* Note: There are 13 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary Positive Allergic Reaction to Amphadase® in the Per-Protocol Population (PPP) Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. A positive reaction consisted of: a) reaction appearing within 30 minutes of drug placement; b) wheal (>8 mm) with or without pseudopods; c) reaction accompanying erythema; and d) reaction accompanying localized itching. Up to 30 minutes after the final study drug injection
Primary Positive Allergic Reaction to Amphadase® in the Intent-to-Treat Population (ITT) Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. A positive reaction consisted of: a) reaction appearing within 30 minutes of drug placement; b) wheal (>8 mm) with or without pseudopods; c) reaction accompanying erythema; and d) reaction accompanying localized itching. Up to 30 minutes after the final study drug injection
Secondary Observed Wheal Size in the Per-Protocol Population (PPP) Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The observed wheal size is the greatest wheal diameter measured at the injection site(s) for a specific study drug injection. Up to 30 minutes after the final study drug injection
Secondary Observed Erythema Size in the Per-Protocol Population (PPP) Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The observed erythema size is the greatest erythema diameter measured at the injection site(s) for a specific study drug injection. Up to 30 minutes after the final study drug injection
Secondary Allergic Wheal Size in the Per-Protocol Population (PPP) Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The allergic wheal size is the greatest wheal diameter with accompanying erythema and localized itching measured at the injection site(s) for a specific study drug injection. Up to 30 minutes after the final study drug injection
Secondary Allergic Erythema Size in the Per-Protocol Population (PPP) Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The allergic erythema size is the greatest erythema diameter with accompanying localized itching measured at the injection site(s) for a specific study drug injection. Up to 30 minutes after the final study drug injection
Secondary Local Itchiness Rate in the Per-Protocol Population (PPP) Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The local itchiness rate is the percentage of subjects that reported localized itching at the injection site(s) for a specific study drug injection. Up to 30 minutes after the final study drug injection
Secondary Erythema Responder Rate in the Per-Protocol Population (PPP) Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The erythema responder rate is the percentage of subjects that showed an erythema reaction at the injection site(s) for a specific study drug injection. Up to 30 minutes after the final study drug injection
Secondary Observed Wheal Size in the Intent-to-Treat Population (ITT) Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The observed wheal size is the greatest wheal diameter measured at the injection site(s) for a specific study drug injection. Up to 30 minutes after the final study drug injection
Secondary Observed Erythema Size in the Intent-to-Treat Population (ITT) Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The observed erythema size is the greatest erythema diameter measured at the injection site(s) for a specific study drug injection. Up to 30 minutes after the final study drug injection
Secondary Allergic Erythema Size in the Intent-to-Treat Population (ITT) Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The allergic erythema size is the greatest erythema diameter with accompanying localized itching measured at the injection site(s) for a specific study drug injection. Up to 30 minutes after the final study drug injection
Secondary Local Itchiness Rate in the Intent-to-Treat Population (ITT) Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The local itchiness rate is the percentage of subjects that reported localized itching at the injection site(s) for a specific study drug injection. Up to 30 minutes after the final study drug injection
Secondary Erythema Responder Rate in the Intent-to-Treat Population (ITT) Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The erythema responder rate is the percentage of subjects that showed an erythema reaction at the injection site(s) for a specific study drug injection. Up to 30 minutes after the final study drug injection
Secondary Allergic Wheal Size in the Intent-to-Treat Population (ITT) Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The allergic wheal size is the greatest wheal diameter with accompanying erythema and localized itching measured at the injection site(s) for a specific study drug injection. Up to 30 minutes after the final study drug injection
See also
  Status Clinical Trial Phase
Completed NCT01425619 - The Effect of Medical Clowns and Topical Anesthetic Cream on Pain and Anxiety in Children Undergoing Allergy Skin Tests N/A
Completed NCT04327752 - Skin Adverse Reactions Occuring in Children Treated by Biotherapy for Chronic Inflammatory Disease
Not yet recruiting NCT05533385 - Juniperus Oxycedrus and Cupressus Arizonica Allergen Extracts Standardisation. N/A
Not yet recruiting NCT05532566 - Quercus Ilex and Quercus Robur Allergen Extracts Standardisation N/A
Recruiting NCT06271993 - SPT for Sensitization of Collagen Dressing N/A